ArticleEuropean journal of medical research2025
Prognostic value of stress hyperglycemia ratio in patients with different plaque types with acute myocardial infarction.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The predictive value of the C-reactive protein-stress hyperglycemia ratio for in-hospital major adverse cardiovascular events in patients with ST-segment elevation myocardial infarction.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
aimThe stress hyperglycemia ratio (SHR) is a novel biomarker that reflects true acute hyperglycemia and has been associated with adverse outcomes and an increased risk of cardiovascular events in patients with myocardial infarction (MI). However, the relationship between SHR and different culprit plaque phenotypes in acute myocardial infarction (AMI) remains unexplored. This study aims to investigate the association between SHR and clinical outcomes in AMI patients stratified by plaque phenotype.
methodsBetween March 2017 and January 2020, a total of 1698 AMI patients were prospectively enrolled. Of these, 364 underwent optical coherence tomography (OCT) to assess culprit lesion morphology. SHR was calculated using the formula: [admission blood glucose (mmol/L)]/[1.59 × HbA1c (%)-2.59]. The primary endpoint was the occurrence of major adverse cardiovascular events (MACEs), defined as a composite of all-cause death, recurrent MI, ischemic stroke, and rehospitalization due to heart failure.
resultsOverall, patients were divided into two groups according to quartile of SHR (Q1-Q3 vs. Q4). After a median follow-up of 4 years, elevated SHR was independently associated with an increased risk of MACEs after adjustment (HR: 1.14, 95% CI 1.05-1.24, p = 0.002). In patients with plaque rupture (PR), SHR remained a significant predictor of MACEs after adjustment (HR: 2.09, 95% CI 1.17-3.73, p = 0.013). In contrast, among patients with plaque erosion (PE), no significant difference in MACEs was observed across SHR-based groups (HR: 1.49, 95% CI 0.66-3.38, p = 0.342).
conclusionsThis study demonstrates that AMI patients with elevated SHR (> 1.2) experience significantly worse clinical outcomes compared to those with lower SHR (≤ 1.2). The prognostic value of SHR was particularly evident in patients with PR rather than those with PE, suggesting its utility for risk stratification and guiding precision management in patients with PR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.